reduces the risk of acute cardiac ischemic events (death and/or myocardial infarction)
in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes)
Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μl because no clinical experience exists regarding such patients.
Renal insufficiency : Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.
Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.
Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards.
Allergy to eptifibatide and/or other ingredients.
Severe, uncontrolled hypertension.
Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.
Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.
Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.
Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists.